J&J's DePuy acquisition
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson files a notification and report form under the Hart-Scott-Rodino Act with respect to its $3.5 bil. cash tender offer for the Roche orthopedic products unit ("The Gray Sheet" July 27, p. 7). The HSR waiting period expires on Aug. 19. Separately, DePuy reports a 7% increase in revenues during the second quarter of 1998 to $219.2 mil. Net income rose 8.5% to $35.3 mil., not including a one-time $131.5 mil. charge associated with the acquisition of AcroMed on June 3
You may also be interested in...
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.